Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc (PRGO), a global pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on February 26, 2026. The filing announces the release of earnings results for the fourth quarter ended December 31, 2025, and the full fiscal year 2025. The detailed financial data is contained in the attached press release (Exhibit 99.1), which is not included in the text of this filing.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the existence of these metrics in the attached press release but does not disclose them directly. The Company reports both GAAP and non-GAAP financial measures, including "CORE" metrics that exclude infant formula operations currently under strategic review and previously announced divestitures.
Material Changes and Adjustments
While specific comparative figures are absent, the filing details the adjustments made to derive non-GAAP results for the three and twelve months ended December 31, 2025, compared to the prior year periods. Key adjustments include:
- Amortization expense related to acquired intangible assets.
- Unusual litigation costs.
- Restructuring charges and termination benefits.
- Impairment charges.
- Gains or losses on divestitures and brand sales.
- Infant formula remediation and related charges.
- Foreign currency translation movements.
- Loss on early debt extinguishment (specifically noted for the 2024 period).
Guidance, Outlook, and Risks
The Company states it cannot reconcile its "All-in" or "CORE" expected organic net sales growth, adjusted margins, or earnings per share to GAAP measures without unreasonable effort. This limitation is due to items outside the Company's control or that cannot be reasonably predicted, including:
- Uncertainty regarding non-recurring infant formula-related charges.
- The timing and amount of future restructuring charges.
- Income tax effects of the aforementioned items.
Management utilizes non-GAAP measures for planning, forecasting, and compensation determinations, emphasizing that these measures should be viewed alongside GAAP results.
Investor Verification Checklist
- Verify specific Q4 and full-year 2025 revenue, net income, and EPS figures in the attached Exhibit 99.1 press release.
- Confirm the magnitude of "CORE" adjustments, specifically the exclusion of infant formula operations.
- Review the reconciliation tables for non-GAAP to GAAP measures to understand the impact of litigation and restructuring charges.
- Assess the uncertainty surrounding future infant formula remediation costs and their potential impact on liquidity.
- Check the status of the strategic review of the infant formula business and any pending divestitures.